Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | LYN | P07948 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MARK3 | P27448 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13728 | 0.90 | KDR (0.34) | PARP1LYNFGFR1KDRROCK2 | |
| SCHEMBL13760 | 0.90 | LYN (0.33) | PARP1LYNFGFR1KDRROCK2 | |
| SCHEMBL13637 | 0.90 | LYN (0.36) | PARP1LYNFGFR1KDRROCK2 | |
| SCHEMBL14850206 | 0.88 | S1PR1 (0.38) | LYNFGFR1KDRROCK2LIMK1 | |
| SCHEMBL14850197 | 0.87 | PARP1 (0.33) | PARP1LYNFGFR1KDRROCK2 | |
| SCHEMBL14069 | 0.86 | LYN (0.34) | PARP1LYNFGFR1KDRROCK2 | |
| SCHEMBL13849 | 0.86 | S1PR1 (0.39) | LYNFGFR1KDRROCK2LIMK1 | |
| SCHEMBL17354214 | 0.85 | KDR (0.40) | HTTLYNFGFR1KDRROCK2 | |
| SCHEMBL17354209 | 0.85 | HDAC3 (0.35) | PARP1ROCK2LIMK1CYP2D6KCNH2 | |
| SCHEMBL14850210 | 0.85 | LYN (0.33) | PARP1LYNFGFR1KDRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845297-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | HTT 1768/4885PARP1 1324/4885LYN 3581/4885 |
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | HTT 1768/4885PARP1 1324/4885LYN 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.